[9]
Nall, R.R.M.C. What to Know About. Med. In: News Today; , 2000; p. 1-2.
[53]
Sathyanarayana, R.; Poojary, B.; Srinivasa, S.M.; Merugumolu, V.K.; Chandrashekarappa, R.B.; Rangappa, S. In vitro, in vivo and in silico-driven identification of novel benzimidazole derivatives as anticancer and anti-inflammatory agents. J. Iranian Chem. Soc, 2021, 22, 1-7.
[55]
Yadav, S.; Narasimhan, B.; Lim, S.M.; Ramasamy, K.; Vasudevan, M.; Shah, S.A.; Mathur, A. Synthesis and evaluation of antimicrobial, antitubercular and anticancer activities of benzimidazole derivatives. Egypt. J. Basic Appl. Sci., 2018, 5(1), 100-109.
[66]
Mantu, D.; Antoci, V.; Moldoveanu, C.; Zbancioc, G. Hybrid imidazole (benzimidazole)/pyridine (quinoline) derivatives and evaluation of their anticancer and antimycobacterial activity. J. Enzyme Inhib. Med. Chem., 2016, 31, 96-103.
[87]
Camden, J.B. Methods of treating cancer with benzimidazoles. U.S.
Patent 6,262,093, 2001.
[88]
Griffin, R.J.; Calvert, A.H.; Curtin, N.J.; Newell, D.R.; Golding, B.T. Benzimidazole compound. U.S. Patent 6,310,082, 2001.
[89]
Takayama, K.; Kimura, T.; Masuda, N.; Naito, R.; Okamoto, Y.; Koga, Y.; Okada, Y.; Takeuchi, M. Benzimidazole compound. International Patent 068,407, 2002.
[90]
Skalitzky, D.J.; Webber, S.E.; Eastman, B. Benzimidazole inhibitors
of poly (ADP- ribosyl) polymerase. U.S. Patent 0,034,078, 2004.
[91]
Machajewski, T.D.; Hannah, A.; Harwood, E.; Haroldsen, E. Use of benzimidazolequinolinones for treating cancer. Canadian Patent
2,501,932, 2014.
[92]
Pfahl, M. Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases. International
Patent 066,952, 2004.
[93]
Beaulieu, F.; Marinier, A.; Ouellet, C.; Roy, S.; Wittman, M.D. Benzimidazole C-2 heterocycles as kinase inhibitors. U.S. Patent
0,054,655, 2005.
[94]
Breitenbucher, J.G.; Lee-dutra, A.; Neff, D.K. Aryl-substituted
benzimidazole and imidazopyridine ethers as anti- cancer agents. Canadian Patent 2,572,218, 2013.
[95]
Bolger, J.; Castelhano, A.L.; Laufer, R.; Li, A.; Peter, C.; Smith, S.; Sun, Y. N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors.
U.S. Patent 0,035,951, 2006.
[96]
Aso, K.; Mochizuki, M.; Kojima, T.; Kobayashi, K.; Pratt, S.A.; Gyorkos, A.C.; Corrette, C.P.; Cho, S.Y. Benzimidazole compounds. International Patent 051,533, 2008.
[97]
Lawrence, K. 2-((R)-methylpyrrolidin-2-yl)-1H-benzimidazole-4- carboxamide crystalline form 1. Australian Patent 310,781, 2009.
[98]
Kamal, A.; Praveen, K.P.; Seshadri, B.N.; Sreekanth, K. Novel
benzimidazole linked pyrrolo[2,1-Q[1,4] benzodiazepine hybrids as
potential antitumour agents and process for the preparation thereof. International Patent 113,085, 2009.
[99]
Goh, K.L.; Khng, H.H.; Sabanayagam, V.M.; Sangthongpitag, K.; Stunkel, W.; Tan, Y.C.; Wood, J.M. Combination of benzimidazole anti-cancer agent and a second anti-cancer agent. U.S. Patent
0,098,691, 2010.
[100]
Boezio, A.; Cheng, A.C.; Coats, J.R.; Copeland, K.W.; Graceffa, R.; Harmange, J.C.; Huang, H.; La, D.; Olivieri, P.R.; Peterson, E.A.; Schenkel, L. Indole/Benzimidazole compounds as Mtor Kinase inhibitors. International Patent 096,314, 2010.
[101]
Reweastle, G.W.; Gamage, S.A.; Flanagan, J.U.; Giddens, A.C.; Tsang, K.Y. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy. U.S. Patent 249,099, 2010.
[102]
Rewcastle, G.W.; Tsang, K.Y.; Gamage, S.A.; Giddens, A.C. Pyrimidinyl
and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy. Canadian Patent 2,767,008, 2018.
[103]
Nair, S.K.; Planken, S.P. Benzimidazole derivatives. Canadian Patent 2,772,194, 2011.
[104]
Rewcastle, G.W.; Giddens, A.C.; Gamage, S.A. 1,3,5- triazinylbenzimidazole
sulfonamides and their use in cancer therapy.
International Patent 044,641, 2012.
[105]
Ahmed, K.; Pogula, P.K. Napthalimide-benzimidazole hybrids as
potential antitumor agents and process for the preparation thereof.
U.S. Patent 8,288,387, 2012.
[106]
Chang, C.S.; Guh, J.; Teng, C.; Pan, S.; Chang, W.; Liu, J.; Chang, K.; Kuo, S. Benzimidazole compounds and their use as anticancer agents. U.S. Patent 8,501,957, 2013.
[107]
Moussy, A.; Benjahad, A.; Schalon, C.; Pez, D.; Chevenier, E.; Sandrinelli, F.; Martin, J.; Picoul, W. Benzimidazole derivatives as selective protein kinase inhibitors. International Patent 202,763, 2014.
[108]
Rehwinkel, H.; Panknin, O.; Ring, S.; Anlauf, S.; Siebeneicher, H.; Nguyen, D.; Schwede, W.; Bauser, M.; Zimmermann, K.; Kaulfuss, S.; Neuhaus, R.; Blaney, P.M. Benzimidazol-2-amines as mIDH1 inhibitors. Australian Patent 217,788, 2015.
[109]
Qu, J.; Rivero, R.; Sanchez, R.; Tedesco, R. Benzimidazole derivatives as Pl3 kinase inhibitors. European Patent 2,624,696, 2016.
[110]
Owens, T.; Hill, R.J. Benzimidazole derivatives as RLK and ITK inhibitors. U.S. Patent 9,932,329, 2018.
[111]
Kim, J.; Song, K.; Kim, T. Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-virus agent comprising the same. U.S. Patent 395,289, 2021.